Harvoni
E409697
Harvoni is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Harvoni canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4050930 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Harvoni Context triple: [Gilead Sciences, product, Harvoni]
-
A.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
B.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
-
E.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Harvoni Target entity description: Harvoni is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection.
-
A.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
B.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
-
E.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
antiviral medication
ⓘ
combination drug ⓘ direct-acting antiviral ⓘ prescription drug ⓘ |
| achievesOutcome | sustained virologic response in many patients ⓘ |
| approvedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| approvedIn |
European Union
ⓘ
United States ⓘ
linked to:
United States of America
|
| canBeUsedIn | HIV/HCV coinfected patients ⓘ |
| contraindicatedWith |
St. John’s wort
ⓘ
linked to:
St John’s wort
rifampin ⓘ strong P-glycoprotein inducers ⓘ |
| developedBy |
Gilead Sciences
ⓘ
linked to:
Gilead Sciences (board member)
|
| hasActiveIngredient |
ledipasvir
ⓘ
sofosbuvir ⓘ
linked to:
Sovaldi
|
| hasATCCode | J05AX65 ⓘ |
| hasBlackBoxWarning | risk of hepatitis B virus reactivation in coinfected patients ⓘ |
| hasCommonAdverseEffect |
diarrhea
ⓘ
fatigue ⓘ headache ⓘ insomnia ⓘ nausea ⓘ |
| hasDosageForm | film-coated tablet ⓘ |
| hasLegalStatus | prescription-only ⓘ |
| hasPregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasRouteOfElimination |
biliary excretion
ⓘ
renal excretion of sofosbuvir metabolites ⓘ |
| hasTarget |
HCV NS5A protein
ⓘ
HCV NS5B RNA-dependent RNA polymerase ⓘ |
| indicatedFor |
adult patients with chronic hepatitis C
ⓘ
patients with cirrhosis ⓘ patients with compensated liver disease ⓘ pediatric patients with chronic hepatitis C ⓘ |
| mechanismOfAction |
NS5A inhibitor activity via ledipasvir
ⓘ
NS5B polymerase inhibitor activity via sofosbuvir ⓘ |
| metabolizedBy | not significantly via CYP450 enzymes ⓘ |
| oftenCoAdministeredWith | ribavirin ⓘ |
| regimenType | interferon-free ⓘ |
| takenOnce | daily ⓘ |
| treats |
chronic hepatitis C virus infection
ⓘ
hepatitis C genotype 1 ⓘ hepatitis C genotype 4 ⓘ hepatitis C genotype 5 ⓘ hepatitis C genotype 6 ⓘ |
| typicalTreatmentDuration |
12 weeks
ⓘ
24 weeks ⓘ 8 weeks ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Harvoni Description of subject: Harvoni is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject linked to:
Gilead Sciences (board member)